Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 5, 2011, Pages 488-493

  Matsuo, Koji ^a,c   Eno, Michele L ^d   Ahn, Edward H ^e   Shahzad, Mian M K ^a,b,g   Im, Dwight D ^e,f   Rosenshein, Neil B ^e,f   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f MERCY MEDICAL CENTER   (United States)

^g UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

biomarker; brain metastasis; MDR 1; multi drug resistance gene; ovarian cancer

Indexed keywords

CARBOPLATIN; CD31 ANTIGEN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEMCITABINE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN P53; TOPOTECAN;

ADULT; ANEUPLOIDY; ARTICLE; BRAIN METASTASIS; CANCER RECURRENCE; CANCER STAGING; CELL CYCLE S PHASE; CRANIOTOMY; CYTOREDUCTIVE SURGERY; DISTANT METASTASIS; EPITHELIAL OVARIAN CANCER; EXTERNAL BEAM RADIOTHERAPY; FALLOPIAN TUBE CANCER; FEMALE; FEMALE GENITAL TRACT CANCER; GENE MUTATION; HUMAN; HUMAN TISSUE; INTESTINE RESECTION; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; PERITONEUM CANCER; PROTEIN EXPRESSION; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SPLEEN METASTASIS; TREATMENT RESPONSE; TUMOR LOCALIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; BRAIN NEOPLASMS; CARBOPLATIN; CISPLATIN; COHORT STUDIES; COMBINED MODALITY THERAPY; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FALLOPIAN TUBE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 80053382419     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181ec5f4b     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. Int J Gynaecol Obstet. 2003;83(suppl 1):135-166. (Pubitemid 39658498)
3. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1-6. (Pubitemid 26012496)
4. Loizzi V, Chan JK, Osann K, et al. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol. 2003; 189:1301-1307. (Pubitemid 37542162)
5. Kolomainen DF, Larkin JM, Badran M, et al. Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence. J Clin Oncol. 2002;20: 982-986. (Pubitemid 34141841)
6. Kastritis E, Efstathiou E, Gika D, et al. Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy. Int J Gynecol Cancer. 2006;16:994-999. (Pubitemid 43886716)
7. Tay SK, Rajesh H. Brain metastases from epithelial ovarian cancer. Int J Gynecol Cancer. 2005;15:824-829.
8. Kaminsky-Forrett MC, Weber B, Conroy T, et al. Brain metastases from epithelial ovarian carcinoma. Int J Gynecol Cancer. 2000;10:366-371.
9. Anupol N, Ghamande S, Odunsi K, et al. Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastases. Gynecol Oncol. 2002;85:487-492. (Pubitemid 34651890)
10. Cohen ZR, Suki D, Weinberg JS, et al. Brain metastases in patients with ovarian carcinoma: prognostic factors and outcome. J Neurooncol. 2004;66:313-325. (Pubitemid 38259814)
11. Porzio G, Ronzino G, Farina E, et al. Cerebral metastasis from ovarian cancer treated with a multidisciplinary approach: case report and review of literature. Eur J Gynecol Oncol. 2003; 24:563-564. (Pubitemid 37462583)
12. Kim TJ, Song S, Kim CK, et al. Prognostic factors associated with brain metastases from epithelial ovarian carcinoma. Int J Gynecol Cancer. 2007;17:1252-1257. (Pubitemid 350077360)
13. McMeekin DS, Kamelle SA, Vasilev SA, et al. Ovarian cancer metastatic to the brain: what is the optimal management? J Surg Oncol. 2001;78:194-200. (Pubitemid 33021084)
14. Cormio G, Maneo A, Colamaria A, et al. Surgical resection of solitary brain metastasis from ovarian carcinoma: an analysis of 22 cases. Gynecol Oncol. 2003;89:116-119. (Pubitemid 36403657)
15. Growdon WB, Lopez-Varela E, Littell R, et al. Extent of extracranial disease is a powerful predictor of survival in patients with brain metastases from gynecological cancer. Int J Gynecol Cancer. 2008;18:262-268. (Pubitemid 351365211)
16. EDR Assay. Available at: www.oncotech.com. Accessed October 1, 2008.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216. (Pubitemid 30099779)
18. Germann UA. P-glycoprotein-a mediator of multidrug resistance in tumour cells. Eur J Cancer. 1996;32A:927-944.
19. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615-627. (Pubitemid 34177898)
20. Kamazawa S, Kigawa J, Kanamori Y, et al. Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol. 2002;86:171-176. (Pubitemid 34953500)
21. Naniwa J, Kigawa J, Kanamori Y, et al. Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17:76-82. (Pubitemid 46213973)
22. Ikeda K, Sakai K, Yamamoto R, et al. Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer. Int J Gynecol Cancer. 2003;13:776-784. (Pubitemid 38235222)
23. Matsuo K, Bond VK, Eno ML, et al. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer. Int J Cancer. 2009;125:2721-2727.
24. Gréen H, Söderkvist P, Rosenberg P, et al. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res. 2006; 12:854-859. (Pubitemid 43259868)
25. Johnatty SE, Beesley J, Paul J, et al. ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res. 2008;14:5594-5601.
26. Sun H, Dai H, Shaik N, et al. Drug efflux transporters in the CNS. Adv Drug Deliv Rev. 2003;55:83-105. (Pubitemid 36082883)
27. Kallioniemi OP, Punnonen R, Mattila J, et al. Prognostic significance of DNA index, multiploidy, and S-phase fraction in ovarian cancer. Cancer. 1988;61:334-339. (Pubitemid 18056493)
28. Matsuo K, Eno ML, Im DD, et al. Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas. Arch Gynecol Obstet. 2010; 281:325-328.
29. Hua J, Mutch DG, Herzog TJ. Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line. Gynecol Oncol. 2005;98:31-38. (Pubitemid 40826415)
30. Yadav S, van Vlerken LE, Little SR, et al. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharmacol. 2009;63:711-722.